ANEB
Anebulo Pharmaceuticals, Inc.
$0.46
+0.00
(-3.36%)
Mkt Cap
18.76M
Volume
1,300
52W Range
0.3-3.42
Sector
Healthcare
Beta
-1.94
EPS (TTM)
-0.19
P/E Ratio
-5.74
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (8.48M) | (8.20M) | (11.73M) | (6.83M) | (30.25M) | (174,637) |
| EPS | -0.25 | -0.32 | -0.47 | -0.29 | -1.30 | -0.01 |
| Free Cash Flow | (6.35M) | (8.09M) | (9.68M) | (5.44M) | (4.87M) | (150,770) |
| FCF / Share | -0.19 | -0.31 | -0.39 | -0.23 | -0.21 | -0.01 |
| Operating CF | (6.35M) | (8.09M) | (9.68M) | (5.44M) | (4.87M) | (150,772) |
| Total Assets | 12.15M | 4.07M | 11.67M | 15.58M | 21.65M | 3.03M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 201,286 |
| Cash & Equiv | 11.63M | 3.09M | 11.25M | 14.55M | 19.99M | 3.02M |
| Book Value | 11.66M | 3.81M | 10.60M | 15.07M | 21.41M | 2.80M |
| Return on Equity | -0.73 | -2.15 | -1.11 | -0.45 | -1.41 | -0.06 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (2.00M) | (2.16M) | (2.14M) | (1.68M) | (2.46M) | (2.20M) | (1.35M) | (1.65M) | (2.72M) | (2.48M) | (2.50M) | (2.80M) |
| EPS | -0.05 | -0.05 | -0.05 | -0.04 | -0.09 | -0.08 | -0.05 | -0.06 | -0.11 | -0.10 | -0.10 | -0.11 |
| Free Cash Flow | (1.31M) | (1.27M) | (1.65M) | (1.60M) | (1.41M) | (1.69M) | (2.05M) | (1.50M) | (1.81M) | (2.73M) | (2.85M) | (2.19M) |
| FCF / Share | -0.03 | -0.03 | -0.04 | -0.06 | -0.05 | -0.07 | -0.08 | -0.06 | -0.07 | -0.11 | -0.11 | -0.09 |
| Operating CF | (1.31M) | (1.27M) | (1.65M) | (1.60M) | (1.41M) | (1.69M) | (2.05M) | (1.50M) | (1.81M) | (2.73M) | (2.85M) | (2.19M) |
| Total Assets | 9.42M | 10.70M | 12.15M | 14.01M | 15.84M | 2.47M | 4.07M | 6.00M | 7.50M | 9.05M | 11.67M | 14.43M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 9.04M | 10.35M | 11.63M | 13.28M | 15.00M | 1.40M | 3.09M | 5.15M | 6.64M | 8.52M | 11.25M | 14.16M |
| Book Value | 7.94M | 9.74M | 11.66M | 13.46M | 14.96M | 1.90M | 3.81M | 4.99M | 6.49M | 8.33M | 10.60M | 12.94M |
| Return on Equity | -0.25 | -0.22 | -0.18 | -0.12 | -0.16 | -1.16 | -0.35 | -0.33 | -0.42 | -0.30 | -0.24 | -0.22 |
ANEB News
Anebulo Pharmaceuticals (NASDAQ:ANEB) & Replimune Group (NASDAQ:REPL) Critical Comparison
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates
Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC
Anebulo Pharmaceuticals (NASDAQ:ANEB) Trading Down 13.6% – What’s Next?
Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock Price Down 13.6% – What’s Next?
Anebulo Pharmaceuticals Announces Final Results of Tender Offer
Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer